Review: Khovidhunkit W and Shoback DM. Clinical Effects of Raloxifene Hydrochloride In

 OSTEOPOROSIS

Review: Manolagas SC and Jilka RL. Bone Marrow, Cytokines, and Bone Remodeling; Emerging insights into the Pathophysiology of Osteoporosis. NEJM 1995;332:305-311.

Review: Khovidhunkit W and Shoback DM. Clinical Effects of Raloxifene Hydrochloride in Women. Ann Int Med 1999;130:431-438.

Review: Kamel HK, Perry HM and Morley JE. Hormone Replacement Therapy and Fractures in Older Adults. JAGS 2001;49:179-187.

Review: Khosla, Sundeep. Oestrogen, Bones and Men: When Testosterone Just Isn’t Enough. Clinical Endocrinology 2002;56:291-293.

Review: Burgess E and Nanes M. Osteoporosis in Men: Pathophysiology, Evaluation and Therapy. Curr Opinion Rheum 2002;14:421-428.

Review: Favus M. Bisphosphonates for Osteoporosis. NEJM 2010;363:2027-35.

Aloia JF, Cohn SH, Vaswani A, Yeh JK, Yuen K and Ellis K. Risk Factors for Postmenopausal Osteoporosis. Am J Med 1985;78:95-100.

Aloia JF, Vaswani A, Yeh JK, Ross PL, Flaster E and Dilmanian A. Calcium Supplementation with and without Hormone Replacement Therapy to Prevent Postmenopausal Bone Loss. Ann Int Med 1994;120:97-103.

McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan GEH, Reda C, Yates AJ and Ravn P. Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis. Ann Int Med 1998;128:253-261.

Hosking D, Chilvers CED, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M and Yates AJ. Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age. NEJM 1998;338:485-492.

Recker RR, Davies M, Dowd RM and Heaney RP. The Effect of Low-Dose Continuous Estrogen and Progesterone Therapy with Calcium and Vitamin D on Bone in Elderly Women. Ann Int Med 1999;130:897-904.

Snyder P, Peachey H, Hannoush P et al. Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age. J Clin Endocrin Metab 1999;84:1966-1972.

Kannus P, Parkkari J, Niemi S, Pasanen M, Palvavev M, Jarvinen M and Vuori I. Prevention of Hip Fracture in Elderly People with Use of a Hip Protector. NEJM 2000;343:1506-1513.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K and Lombardi A. Alendronate for the Treatment of Osteoporosis in Men. NEJM 2000;343:606-610.

Amin S, Zhang Y, Sawin C, Evans S, Hannan M, Kiel D, Wilson P and Felson D. Association of Hypogonadism and Estradiol Levels with Bone Mineral Density in Elderly Men from the Framingham Study. Ann Int Med 2000;133:951-963.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish- Shalom S, Genant HK, Wang O and Mitlak BH. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. NEJM 2001;344:1434-1441. Boonen S et al. Safety and Efficacy of Risedronate in Reducing Fracture Risk in Osteoporotic Women Aged 80 and Older. JAGS 2004;52:1832-9.

Black DM et al. One Year of Alendronate after One Year of Parathyroid Hormone (1-84) for Osteoporosis. NEJM 2005;353:555-65.

Cosman F et al. Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate. NEJM 2005;353:566-75.

Lyles KW et al. Zoledronic Acid and Clinical Hip Fractures and Mortality after Hip Fracture. NEJM 2007;357:1799-809.

Boonen S et al. Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. NEJM 2012; 367:1714-23.